Newly-elected chairman of Wegovy-maker Novo Nordisk , Lars Rebien Sorensen, said on Friday he plans to enhance the board's ...

WeightWatchers' CEO said on Wednesday it planned to offer Novo Nordisk's much-anticipated Wegovy in pill form if it is ...

(Reuters) -Mikael Dolsten, Pfizer's former research and development chief, has withdrawn his candidacy for Novo Nordisk's ...

After [losing out to Pfizer]( ...

By Rishika Sadam BENGALURU (Reuters) -Danish drugmaker Novo Nordisk on Tuesday cut the price of its blockbuster weight-loss ...

WeightWatchers' CEO said on Wednesday it plans to sell Novo Nordisk's much-anticipated Wegovy in pill form if it is launched ...

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...

Novo Nordisk A/S remains attractive with strong cash flow and robust pipeline. Click here to read why NVO stock is a Buy.

Lars Rebien Sorensen is back as chairman of Novo Nordisk A/S following a shareholder meeting that exposed the depth of rivalry between the Danish drugmaker and US arch nemesis Pfizer Inc.

Shares of Novo Nordisk A/S (NYSE: NVO) dropped 1.9%today, closing at $48.25, just a whisker above the 52-week low of $45.05.

Novo Nordisk A/S growth is driven by global obesity drug demand, robust pipeline development and manufacturing scale. Read ...

The boardroom shake-up, which erupted when Novo's board Chair Helge Lund and the independent members stepped down last month ...